For research use only. Not for therapeutic Use.
BCR-ABL-IN-8(CAT: I040573) is a highly potent small-molecule inhibitor of the BCR-ABL fusion tyrosine kinase, a key oncogenic driver in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This compound effectively suppresses both wild-type and select mutant forms of BCR-ABL, including T315I, which confers resistance to first-generation inhibitors. BCR-ABL-IN-8 disrupts downstream signaling pathways critical for leukemic cell proliferation and survival. It is an essential research tool for studying resistance mechanisms and evaluating combination therapies in kinase-driven malignancies. Suitable for in vitro kinase assays and in vivo cancer models, BCR-ABL-IN-8 supports targeted therapy and precision oncology research.
| CAS Number | 1808288-49-4 |
| Synonyms | 2-(3-amino-4-methylanilino)-4-(methylamino)-N-[2-methyl-5-[(3,4,5-trimethoxybenzoyl)amino]phenyl]pyrimidine-5-carboxamide |
| Molecular Formula | C30H33N7O5 |
| Purity | ≥95% |
| IUPAC Name | 2-(3-amino-4-methylanilino)-4-(methylamino)-N-[2-methyl-5-[(3,4,5-trimethoxybenzoyl)amino]phenyl]pyrimidine-5-carboxamide |
| InChI | InChI=1S/C30H33N7O5/c1-16-7-9-19(13-22(16)31)35-30-33-15-21(27(32-3)37-30)29(39)36-23-14-20(10-8-17(23)2)34-28(38)18-11-24(40-4)26(42-6)25(12-18)41-5/h7-15H,31H2,1-6H3,(H,34,38)(H,36,39)(H2,32,33,35,37) |
| InChIKey | WIXKMJHLNQXNOI-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)NC2=NC=C(C(=N2)NC)C(=O)NC3=C(C=CC(=C3)NC(=O)C4=CC(=C(C(=C4)OC)OC)OC)C)N |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
